Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 5/20 | 0.42 |
| ▸ | TMPRSS6 | Q8IU80 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 2/20 | 0.39 |
| ▸ | TCF4 | P15884 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | LOX | P28300 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL781868 | 0.91 | CYP2C19 (0.49) | F2ALDH1A1AKR1C3SMN1; SMN2KMT2A | |
| SCHEMBL7667753 | 0.78 | F2 (0.52) | F2TMPRSS6ALDH1A1HPGDAKR1C3 | |
| SCHEMBL782653 | 0.76 | F2 (0.53) | F2TMPRSS6ALDH1A1AKR1C3SLC40A1 | |
| SCHEMBL781872 | 0.71 | ALDH1A1 (0.45) | ALDH1A1STAT3KDM4EKMT2ASLC40A1 | |
| SCHEMBL22557351 | 0.71 | CYP2C19 (0.56) | ALDH1A1HPGDAKR1C3KMT2ASLC40A1 | |
| SCHEMBL11278869 | 0.70 | SLC40A1 (0.56) | F2ALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL782654 | 0.69 | SMN1; SMN2 (0.44) | ALDH1A1STAT3SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL28258569 | 0.69 | CYP2C19 (0.53) | F2ALDH1A1AKR1C3SLC40A1LMNA | |
| SCHEMBL19489940 | 0.69 | TSHR (0.53) | ALDH1A1HPGDAKR1C3SMN1; SMN2KDM4E | |
| SCHEMBL3476507 | 0.69 | TDP1 (0.60) | ALDH1A1HPGDKDM4EKMT2ASLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105440032-B | Pyrazines derivatives as ENAC blocking agents | 诺华股份有限公司 | 2017-12-08 | — | — | CN | disclosed |
| US-20170143705-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2017-05-25 | — | — | US | disclosed |
| US-9522149-B2 | Pyrazine derivatives as ENaC blockers | NOVARTIS AG (CH) | 2016-12-20 | — | — | US | disclosed |
| CN-105440032-A | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG | 2016-03-30 | — | — | CN | disclosed |
| CN-103249723-B | Pyrazine derivatives as ENAC blockers | NOVARTIS AG (CH) | 2015-11-25 | — | — | CN | disclosed |
| US-20150224098-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2015-08-13 | — | — | US | disclosed |
| US-9050339-B2 | Pyrazine derivatives as ENaC blockers | NOVARTIS AG (CH) | 2015-06-09 | — | — | US | disclosed |
| EP-2616447-B1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2015-02-18 | — | — | EP | disclosed |
| US-20140113914-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2014-04-24 | — | — | US | disclosed |
| CN-103249723-A | Pyrazine derivatives as enac blockers | NOVARTIS AG | 2013-08-14 | — | — | CN | disclosed |
| EP-2616447-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-8372845-B2 | Pyrazine derivatives as enac blockers | NOVARTIS AG (CH) | 2013-02-12 | — | — | US | disclosed |
| US-20120071479-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| WO-2012035158-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113914-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | F2 2273/4885TMPRSS6 1010/4885ALDH1A1 2428/4885 |
| US-20150224098-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | F2 2273/4885TMPRSS6 1010/4885ALDH1A1 2428/4885 |
| US-20170143705-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | F2 2273/4885TMPRSS6 1010/4885ALDH1A1 2428/4885 |
| US-20120071479-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | F2 2273/4885TMPRSS6 1010/4885ALDH1A1 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.